Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by ANALIAS00on Jul 23, 2019 1:09pm

98 Views

Post# 29951528

RE:RE:RE:RE:RE:Bad information

So what ? I hope they feel that we care about our own interest. And I hope you are not blaming anyone to report such wrong article. They must take in consideration those serious investors that we are on this board. Of course there will always be some less serious one but others must be listened

jfm1330 wrote: Dubuc and the rest of management must think we are a bunch of intense people around here!

scarlet1967 wrote: That is a quick response to my email:

Philippe Dubuc via theratech.onmicrosoft.com

10:56 AM (1 hour ago)

to me

We have already contacted them to provide more up to date information.